A Double-Blind, Placebo-Controlled Pilot Study of Galantamine to Improve Cognitive Dysfunction in Minimally Symptomatic Bipolar Disorder

S NASSIR GHAEMI; William S GILMER; Robert T DUNN; Robert E HANLON; David E KEMP; Amber D BAUER; Lyvia CHRIKI; Megan M FILKOWSKI; Philip D HARVEY

doi:10.1097/JCP.0b013e3181a497d7

Back

A Double-Blind, Placebo-Controlled Pilot Study of Galantamine to Improve Cognitive Dysfunction in Minimally Symptomatic Bipolar Disorder

Journal article

Peer reviewed

A Double-Blind, Placebo-Controlled Pilot Study of Galantamine to Improve Cognitive Dysfunction in Minimally Symptomatic Bipolar Disorder

S NASSIR GHAEMI, William S GILMER, Robert T DUNN, Robert E HANLON, David E KEMP, Amber D BAUER, Lyvia CHRIKI, Megan M FILKOWSKI and Philip D HARVEY

Journal of clinical psychopharmacology, Vol.29(3), pp.291-295

2009

DOI: https://doi.org/10.1097/JCP.0b013e3181a497d7

PMID: 19440086

Abstract

Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer

Psychology. Psychoanalysis. Psychiatry

Adult and adolescent clinical studies

Psychopharmacology

Pharmacology. Drug treatments

Psychopathology. Psychiatry

Mood disorders

Biological and medical sciences

Medical sciences

Neuropharmacology

Bipolar disorders

Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)

Metrics

17 Record Views

24 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.21 Psychiatry; 1.21.739 Bipolar Disorder
Web Of Science research areas: Pharmacology & Pharmacy; Psychiatry
ESI research areas: Neuroscience & Behavior

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: A Double-Blind, Placebo-Controlled Pilot Study of Galantamine to Improve Cognitive Dysfunction in Minimally Symptomatic Bipolar Disorder
Creators: S NASSIR GHAEMI - Department of Psychiatry, Mood Disorders Program, Tufts Medical Center, Boston, MA, United States
William S GILMER - Asher Center for the Study and Treatment of Depressive Disorders, Northwestern University, Chicago, IL, United States
Robert T DUNN - Bipolar Disorder Research Program, Cambridge Health Alliance/Harvard Medical School, Cambridge, MA, United States
Robert E HANLON - Asher Center for the Study and Treatment of Depressive Disorders, Northwestern University, Chicago, IL, United States
David E KEMP - Department of Psychiatry, Case Westem Reserve University, Cleveland, OH, United States
Amber D BAUER - Asher Center for the Study and Treatment of Depressive Disorders, Northwestern University, Chicago, IL, United States
Lyvia CHRIKI - Bipolar Disorder Research Program, Cambridge Health Alliance/Harvard Medical School, Cambridge, MA, United States
Megan M FILKOWSKI - Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, United States
Philip D HARVEY - Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, United States
Publication Details: Journal of clinical psychopharmacology, Vol.29(3), pp.291-295
Publisher: Lippincott Williams & Wilkins; Hagerstown, MD
Academic Unit: Miller School of Medicine; UMMG Dept of Psychiatry & Behavioral Sciences
Language: English
Resource Type: Journal article
PMID: 19440086
Record Identifier: 991031559443002976